AstraZeneca’s Breast Cancer Drug Falls Short | Johannesburg News

AstraZeneca’s promising breast cancer drug, camizestrant (Etcamah), stumbled in a major late-stage trial, failing to show statistically significant benefits when paired with Pfizer’s Ibrance—just one week after earning FDA approval for certain patients. The setback led to a dip in AstraZeneca’s stock and dashed hopes of $5 billion in peak sales, mostly from early-stage use. While the trial involved over 1,300 hormone-driven advanced breast cancer patients, analysts weren’t entirely shocked, given prior failures by competitors like Roche and cautious pre-trial comments from AstraZeneca. The company plans to unveil full data at an upcoming medical conference, but the drug still holds accelerated approval for a specific patient subgroup. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9629848a8b54c917